Sonoma Pharmaceuticals, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

3. Summary of Significant Accounting Policies (Tables)

3. Summary of Significant Accounting Policies (Tables)

3 Months Ended

Jun. 30, 2020

	Three Months Ended
	June 30,
	2020		2019
Numerator:
Income from continuing operations	$	39,000	$	531,000
Income from discontinued operations		954,000		184,000
Net income	$	993,000	$	715,000

Denominator:
Weighted-average number of common shares outstanding: basic		1,839,000		1,316,000
Common stock to be issued upon vesting of restricted stock units		4,000		3,000
Conversion of Series C		–		17,000
Weighted-average number of common shares outstanding: diluted		1,843,000		1,336,000

Income per share from continuing operations	$	0.02	$	0.40
Income per share from discontinued operations		0.52		0.14
Net income per share: basic and diluted	$	0.54	$	0.54

Schedule of antidilutive shares

The computation of basic loss per share for the three months ended June 30, 2020 and 2019 excludes the potentially dilutive securities summarized in the table below because their inclusion would be anti-dilutive.

	June 30,
	2020		2019
Common stock to be issued upon vesting of restricted stock units		5,000		–
Common stock to be issued upon exercise of options		252,000		155,000
Common stock to be issued upon exercise of warrants		169,000		446,000
Common stock to be issued upon exercise of common stock units (1)		46,000		46,000
		472,000		647,000

(1)	Consists of 30,668 restricted stock units and warrants to purchase 15,332 shares of common stock

Disaggregated Revenue by Source

	Three Months Ended June 30,
Product	2020		2019
Human Care	$	6,864,000	$	3,962,000
Animal Care		377,000		423,000
Other		13,000		–
Total	$	7,254,000	$	4,385,000